MBMA vs. Meta-Analysis: Quick Comparison Guide
Discover how Model-Based Meta-Analysis (MBMA) outperforms traditional meta-analysis in drug development by predicting outcomes, informing…
CertaraOctober 8, 2025
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions
Replace TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA. Learn more…
CertaraOctober 3, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
CertaraOctober 2, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
The Top 10 Things You Need to Know About ADNCA Datasets
Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…
CertaraSeptember 11, 2025
